$1.54
+0.05 (+3.36%)
Open$1.52
Previous Close$1.49
Day High$1.64
Day Low$1.52
52W High$13.48
52W Low$0.89
Volume—
Avg Volume266.6K
Market Cap25.50M
P/E Ratio—
EPS$-3.58
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+2,849.4% upside
Current
$1.54
$1.54
Target
$45.42
$45.42
$30.66
$45.42 avg
$56.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.47M | 17.78M | 17.86M |
| Net Income | 823.9K | 633.2K | 616.7K |
| Profit Margin | 4.5% | 3.6% | 3.5% |
| EBITDA | 1.32M | 1.18M | 1.27M |
| Free Cash Flow | 745.4K | 469.0K | 453.6K |
| Rev Growth | +3.4% | -9.1% | -0.5% |
| Debt/Equity | 0.78 | 0.66 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |